Expert insights. Personalized for you.
Data from Eli Lilly and Company’s (NYSE: LLY) Phase III clinical trial evaluating its monoclonal antibody drugs bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) show that combining the two significantly reduced the risk of COVID-19 hospitalizations and death by 70 percent. MORE
The results show that drugs from both companies can help prevent or treat COVID-19 when given at the right time. But that won't mean much if barriers to use remain high MORE
The pharma is the first to seek emergency approval for this kind of treatment, and may quickly follow up with a second request after reporting promising data for a two-drug combination MORE
drugmaker is the latest to invest large sums of money in antibody-drug conjugates, following recent deals by Gilead, Merck and AstraZeneca The U.S. MORE
Moderna and Gilead reported billions in sales for their coronavirus treatments, but Regeneron's antibody drug cocktail hasn't gained traction. MORE
billion, Boehringer will take control of NBE-Therapeutics and its antibody drug conjugate technology, which has already produced one clinical-stage therapy For about $1.4 MORE
According to Lilly, the NIAID took its decision on the strength of trial data which indicated that bamlanivimab – an antibody that neutralises the SARS-CoV-2 coronavirus – was unlikely to help hospitalised patients recover from advanced-stage COVID-19. MORE
The results could raise doubts about the ability of synthetic antibody drugs to help patients already very sick with COVID-19 MORE
Drugs (Pharmaceuticals) Coronavirus (2019-nCoV) Eli Lilly and Company Regeneron Pharmaceuticals Inc Food and Drug Administration Antibodies your-feed-healthcareHere’s information about who these therapies can help, how much they cost and how to find out if you can get them where you live. MORE
Although the world is eagerly awaiting news of an effective and safe vaccine against COVID-19, several companies are moving ahead testing therapeutic antibodies against the disease MORE
A data monitoring board said a study testing Vir's drug should be stopped early because of an overwhelming benefit from treatment MORE
GlaxoSmithKline PLC Food and Drug Administration Drugs (Pharmaceuticals) Antibodies Coronavirus (2019-nCoV The drug, from GlaxoSmithKline and Vir, aims to keep Covid patients out of the hospital. MORE
This is why Regeneron’s announcement of positive clinical trial results that show its antibody cocktail treatment can cut deaths among hospitalized patients is welcome news. Regeneron has enlisted the help of Roche to help manufacture the antibody drug. MORE
But a growing group of antibody drugs, several of which were showcased at ASH, aren't far behind Two cell therapies might soon be approved for the blood cancer. MORE
Pivotal data from Amgen’s and AstraZeneca’s NAVIGATOR Phase III trial show tezepelumab, a potential first-in-class human monoclonal antibody, reduced asthma aggravations and exacerbations requiring hospitalizations better than placebo in patients with severe asthma MORE
The findings could help boost the supply and reach of Regeneron's COVID-19 antibody drug, which, despite limited use, is now backed by convincing data showing it can prevent hospitalization MORE
The emergence of new variants has made antibody drug combinations, which are harder for the virus to evade, more important and led to a unique partnership between a trio of drugmakers MORE
Widespread availability of commercial assays that detect anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies has enabled researchers to examine naturally acquired immunity to coronavirus disease 2019 (COVID-19) at the population level. The study uses national data to expand on an earlier US Centers for Disease Control and Prevention study of seroprevalence of antibodies to SARS-CoV-2 in 10 US sites MORE
LSBio Acquires Absolute Antibody Ltd. LSBio Acquires Absolute Antibody Ltd. SEATTLE–(BUSINESS WIRE)–LSBio (LSBio™), a leading provider of antibodies and life science research reagents, is pleased to announce its acquisition of Redcar, UK-based Absolute Antibody, Ltd. MORE
Pharma and biotech companies alike see potential in using bispecific antibodies for hard-to-treat cancers like leukemia, myeloma and solid tumors MORE
The EMA has started reviewing the emergency use application for GlaxoSmithKline and Vir Biotech’s COVID-19 antibody VIR-7831, which could become the fourth drug of its type cleared for early use in the EU. . The post EMA starts review of GSK/Vir COVID-19 antibody appeared first on. MORE
Two antibodies targeting different parts of the COVID-19 virus spike protein, from Eli Lilly and GlaxoSmithKline/Vir Biotech, can cut viral load dramatically within a week. . The post Lilly and GSK/Vir antibody pairing offers resistant COVID-19 hope appeared first on. MORE
The request comes less than six months after the FDA authorized Lilly's bamlanivimab, reflecting the spread of virus variants that can elude the drug MORE
In a late-stage study of people recently diagnosed with COVID-19, the dual-antibody drug sharply reduced the risk of hospitalizations and death MORE
Adagio Therapeutics, a well-financed spinout of antibody developer Adimab, could challenge Regeneron and Eli Lilly if its drug candidate proves protective in clinical tests MORE
The EMA has begun a rolling review of a COVID-19 antibody developed by GlaxoSmithKline and Vir BioTech which could become the fourth drug of its type cleared for early use in the EU. . EMA_News starts evaluating the monoclonal antibody sotrovimab. MORE
Antibody flunks post-exposure prevention study. Eli Lilly meanwhile reported positive results with its bamlanivimab antibody in the BLAZE-2 study carried put in nursing homes, which found a 57% reduction in the risk of infection compared to placebo. MORE
An advisory committee meeting to discuss the antibody is however still due to go ahead as scheduled on 27 May, according to Provention, and the FDA’s priority review is still ongoing. The post Provention faces delay in FDA review of diabetes prevention antibody appeared first on. MORE
internal-essential Coronavirus (2019-nCoV) Drugs (Pharmaceuticals) Antibodies Eli Lilly and CompanyThe government will pay $210 million for the doses, which Eli Lilly will ship by the end of March. MORE
Together, the companies expect to make three and a half times as many doses of Regeneron's antibody drug than the U.S. biotech could on its own MORE
Treatments from Lilly and Regeneron that combine two different antibodies should be used instead, according to health officials MORE
The biotech said it will seek an expanded FDA clearance after results from the RECOVERY trial showed its antibody can lower mortality among certain hospitalized COVID-19 patients MORE
The Food and Drug Administration cleared the company's synthetic antibody treatment, but short supplies and logistical challenges could limit its initial impact MORE
Research for the drug, now cleared as Inmazeb, helped Regeneron jumpstart its fast development of an antibody therapy for COVID-19 MORE
Biogen has four other Alzheimer’s candidates in its clinical pipeline behind recently-approved Aduhelm, but one of them – anti-tau antibody gosuranemab – has just been canned. The post Biogen abandons tau antibody for Alzheimer’s after phase 2 miss appeared first on. MORE
Biodesix Announces Commercial Availability of SARS CoV-2 Neutralization Antibody Test Biodesix Announces Commercial Availability of SARS CoV-2 Neutralization Antibody Test Detection of circulating neutralizing antibodies produced in response to COVID-19 vaccination and infection may benefit immunocompromised individuals. BOULDER, Colo.–(BUSINESS MORE
Merck's deal for Seattle Genetics' antibody-drug conjugate comes as Gilead agreed to acquire rival developer Immunomedics in the biotech industry's largest buyout of 2020 MORE
Buying VelosBio is Merck's second investment in so-called antibody-drug conjugates since September, reflecting the drug class' fast turnaround MORE
Fast antibody testing, however, is spotty The drug, now being considered for emergency clearance by the FDA, seems to work best in patients whose immune systems haven't responded to infection. MORE
Vir's sotrovimab arrives months after similar treatments from Eli Lilly and Regeneron. But the drug could still play a role due to its apparent potency against variants that have challenged Lilly's drugs MORE
internal-essential Drugs (Pharmaceuticals) Antibodies Coronavirus (2019-nCoV Researchers hope Eli Lilly’s new combination therapy may be better able to fight virus variants than a similar treatment already in use. MORE
AstraZeneca is playing catch up with Eli Lilly and Regeneron with its antibody therapy for COVID-19, but aims to narrow the gap with the help of decentralised clinical trial specialist Care Access Research. The post AZ deploys mobile sites to test COVID-19 antibody AZD7442 appeared first on. MORE
The two antibody treatments are now being reviewed by the FDA, although limited supply could mean their impact won't be felt for months, even if they are cleared for use MORE
Antibody Related Topics 
Bio Pharma Dive
JUNE 16, 2021
The biotech said it will seek an expanded FDA clearance after results from the RECOVERY trial showed its antibody can lower mortality among certain hospitalized COVID-19 patients
Bio Pharma Dive
JUNE 18, 2021
drugmaker is the latest to invest large sums of money in antibody-drug conjugates, following recent deals by Gilead, Merck and AstraZeneca The U.S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
FEBRUARY 10, 2021
In a late-stage study of people recently diagnosed with COVID-19, the dual-antibody drug sharply reduced the risk of hospitalizations and death
Bio Pharma Dive
NOVEMBER 9, 2020
The Food and Drug Administration cleared the company's synthetic antibody treatment, but short supplies and logistical challenges could limit its initial impact
Bio Pharma Dive
NOVEMBER 5, 2020
Fast antibody testing, however, is spotty The drug, now being considered for emergency clearance by the FDA, seems to work best in patients whose immune systems haven't responded to infection.
Bio Pharma Dive
MARCH 25, 2021
Treatments from Lilly and Regeneron that combine two different antibodies should be used instead, according to health officials
Bio Pharma Dive
OCTOBER 14, 2020
Research for the drug, now cleared as Inmazeb, helped Regeneron jumpstart its fast development of an antibody therapy for COVID-19
NY Times
FEBRUARY 9, 2021
internal-essential Drugs (Pharmaceuticals) Antibodies Coronavirus (2019-nCoV Researchers hope Eli Lilly’s new combination therapy may be better able to fight virus variants than a similar treatment already in use.
Bio Pharma Dive
MAY 24, 2021
Pharma and biotech companies alike see potential in using bispecific antibodies for hard-to-treat cancers like leukemia, myeloma and solid tumors
Bio Pharma Dive
NOVEMBER 5, 2020
Buying VelosBio is Merck's second investment in so-called antibody-drug conjugates since September, reflecting the drug class' fast turnaround
Bio Pharma Dive
JANUARY 12, 2021
Moderna and Gilead reported billions in sales for their coronavirus treatments, but Regeneron's antibody drug cocktail hasn't gained traction.
Bio Pharma Dive
AUGUST 19, 2020
Together, the companies expect to make three and a half times as many doses of Regeneron's antibody drug than the U.S. biotech could on its own
Bio Pharma Dive
DECEMBER 10, 2020
billion, Boehringer will take control of NBE-Therapeutics and its antibody drug conjugate technology, which has already produced one clinical-stage therapy For about $1.4
Pharma Phorum
MARCH 30, 2021
Two antibodies targeting different parts of the COVID-19 virus spike protein, from Eli Lilly and GlaxoSmithKline/Vir Biotech, can cut viral load dramatically within a week. . The post Lilly and GSK/Vir antibody pairing offers resistant COVID-19 hope appeared first on.
Bio Pharma Dive
MARCH 24, 2021
The findings could help boost the supply and reach of Regeneron's COVID-19 antibody drug, which, despite limited use, is now backed by convincing data showing it can prevent hospitalization
Bio Pharma Dive
MARCH 11, 2021
A data monitoring board said a study testing Vir's drug should be stopped early because of an overwhelming benefit from treatment
Bio Pharma Dive
SEPTEMBER 14, 2020
Merck's deal for Seattle Genetics' antibody-drug conjugate comes as Gilead agreed to acquire rival developer Immunomedics in the biotech industry's largest buyout of 2020
Bio Pharma Dive
OCTOBER 8, 2020
The two antibody treatments are now being reviewed by the FDA, although limited supply could mean their impact won't be felt for months, even if they are cleared for use
NY Times
FEBRUARY 26, 2021
internal-essential Coronavirus (2019-nCoV) Drugs (Pharmaceuticals) Antibodies Eli Lilly and CompanyThe government will pay $210 million for the doses, which Eli Lilly will ship by the end of March.
NY Times
MAY 26, 2021
GlaxoSmithKline PLC Food and Drug Administration Drugs (Pharmaceuticals) Antibodies Coronavirus (2019-nCoV The drug, from GlaxoSmithKline and Vir, aims to keep Covid patients out of the hospital.
XTalks
JUNE 18, 2021
This is why Regeneron’s announcement of positive clinical trial results that show its antibody cocktail treatment can cut deaths among hospitalized patients is welcome news. Regeneron has enlisted the help of Roche to help manufacture the antibody drug.
Bio Pharma Dive
DECEMBER 8, 2020
But a growing group of antibody drugs, several of which were showcased at ASH, aren't far behind Two cell therapies might soon be approved for the blood cancer.
Bio Pharma Dive
OCTOBER 27, 2020
The results could raise doubts about the ability of synthetic antibody drugs to help patients already very sick with COVID-19
Bio Pharma Dive
JANUARY 27, 2021
The emergence of new variants has made antibody drug combinations, which are harder for the virus to evade, more important and led to a unique partnership between a trio of drugmakers
Pharma Phorum
JUNE 15, 2021
Antibody flunks post-exposure prevention study. Eli Lilly meanwhile reported positive results with its bamlanivimab antibody in the BLAZE-2 study carried put in nursing homes, which found a 57% reduction in the risk of infection compared to placebo.
Pharma Phorum
JUNE 17, 2021
Biogen has four other Alzheimer’s candidates in its clinical pipeline behind recently-approved Aduhelm, but one of them – anti-tau antibody gosuranemab – has just been canned. The post Biogen abandons tau antibody for Alzheimer’s after phase 2 miss appeared first on.
BioSpace
MAY 12, 2021
Pivotal data from Amgen’s and AstraZeneca’s NAVIGATOR Phase III trial show tezepelumab, a potential first-in-class human monoclonal antibody, reduced asthma aggravations and exacerbations requiring hospitalizations better than placebo in patients with severe asthma
BioTech 365
JUNE 15, 2021
Biodesix Announces Commercial Availability of SARS CoV-2 Neutralization Antibody Test Biodesix Announces Commercial Availability of SARS CoV-2 Neutralization Antibody Test Detection of circulating neutralizing antibodies produced in response to COVID-19 vaccination and infection may benefit immunocompromised individuals. BOULDER, Colo.–(BUSINESS
Pharma Phorum
MAY 10, 2021
The EMA has begun a rolling review of a COVID-19 antibody developed by GlaxoSmithKline and Vir BioTech which could become the fourth drug of its type cleared for early use in the EU. . EMA_News starts evaluating the monoclonal antibody sotrovimab.
Pharma Phorum
APRIL 9, 2021
An advisory committee meeting to discuss the antibody is however still due to go ahead as scheduled on 27 May, according to Provention, and the FDA’s priority review is still ongoing. The post Provention faces delay in FDA review of diabetes prevention antibody appeared first on.
Pharma Phorum
APRIL 19, 2021
The EMA has started reviewing the emergency use application for GlaxoSmithKline and Vir Biotech’s COVID-19 antibody VIR-7831, which could become the fourth drug of its type cleared for early use in the EU. . The post EMA starts review of GSK/Vir COVID-19 antibody appeared first on.
BioTech 365
DECEMBER 22, 2020
LSBio Acquires Absolute Antibody Ltd. LSBio Acquires Absolute Antibody Ltd. SEATTLE–(BUSINESS WIRE)–LSBio (LSBio™), a leading provider of antibodies and life science research reagents, is pleased to announce its acquisition of Redcar, UK-based Absolute Antibody, Ltd.
Pharma Phorum
JANUARY 27, 2021
AstraZeneca is playing catch up with Eli Lilly and Regeneron with its antibody therapy for COVID-19, but aims to narrow the gap with the help of decentralised clinical trial specialist Care Access Research. The post AZ deploys mobile sites to test COVID-19 antibody AZD7442 appeared first on.
Bio Pharma Dive
JANUARY 26, 2021
The results show that drugs from both companies can help prevent or treat COVID-19 when given at the right time. But that won't mean much if barriers to use remain high
Pharma Phorum
OCTOBER 27, 2020
According to Lilly, the NIAID took its decision on the strength of trial data which indicated that bamlanivimab – an antibody that neutralises the SARS-CoV-2 coronavirus – was unlikely to help hospitalised patients recover from advanced-stage COVID-19.
Bio Pharma Dive
APRIL 16, 2021
The request comes less than six months after the FDA authorized Lilly's bamlanivimab, reflecting the spread of virus variants that can elude the drug
BioSpace
AUGUST 11, 2020
Although the world is eagerly awaiting news of an effective and safe vaccine against COVID-19, several companies are moving ahead testing therapeutic antibodies against the disease
XTalks
JANUARY 29, 2021
Data from Eli Lilly and Company’s (NYSE: LLY) Phase III clinical trial evaluating its monoclonal antibody drugs bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) show that combining the two significantly reduced the risk of COVID-19 hospitalizations and death by 70 percent.
JAMA Internal Medicine
NOVEMBER 23, 2020
Widespread availability of commercial assays that detect anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies has enabled researchers to examine naturally acquired immunity to coronavirus disease 2019 (COVID-19) at the population level. The study uses national data to expand on an earlier US Centers for Disease Control and Prevention study of seroprevalence of antibodies to SARS-CoV-2 in 10 US sites
NY Times
DECEMBER 23, 2020
Drugs (Pharmaceuticals) Coronavirus (2019-nCoV) Eli Lilly and Company Regeneron Pharmaceuticals Inc Food and Drug Administration Antibodies your-feed-healthcareHere’s information about who these therapies can help, how much they cost and how to find out if you can get them where you live.
Bio Pharma Dive
MAY 27, 2021
Vir's sotrovimab arrives months after similar treatments from Eli Lilly and Regeneron. But the drug could still play a role due to its apparent potency against variants that have challenged Lilly's drugs
Bio Pharma Dive
OCTOBER 7, 2020
The pharma is the first to seek emergency approval for this kind of treatment, and may quickly follow up with a second request after reporting promising data for a two-drug combination
74 
Let's personalize your content